Jpmorgan Chase & CO 9 Meters Biopharma, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022
SELL
$0.26 - $0.64 $27,607 - $67,956
-106,182 Reduced 99.84%
167 $0
Q1 2022

May 11, 2022
BUY
$0.52 - $1.0 $10,634 - $20,450
20,450 Added 23.81%
106,349 $64,000
Q3 2021

Nov 12, 2021
BUY
$1.03 - $1.41 $88,475 - $121,117
85,899 New
85,899 $111,000

Others Institutions Holding NMTR

# of Institutions
3
Shares Held
67.9K
Call Options Held
0
Put Options Held
0
View Full List

About 9 METERS BIOPHARMA, INC.

NMTR Quotes by TradingView
  • Ticker NMTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,955,400
  • Market Cap $259K
  • Description
  • 9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...
More about NMTR
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email